Universität Bielefeld

© Universität Bielefeld

Call for Applications


The Marie-Sklodowska-Curie European Training Network Magicbullet :: Reloaded will develop and employ approaches for selective, targeted delivery of a panel of anticancer drugs for directed tumor therapy. The activities of the consortium will be devoted to four different project areas:

  • Small molecule-drug conjugates (SMDCs) and peptide-drug conjugates (PDCs)
  • Multivalency and crosstalk with the immune system
  • Pharmacokinetics: Transport, drug release, and metabolism
  • Biological evaluation of the conjugates

EU This project has received funding from the European Union′s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 861316.

The Marie-Sklodowska-Curie Innovative Training Network (ITN) Magicbullet::Reloaded offers 15 three-years fixed-term PhD positions

The ETN Magicbullet::Reloaded will provide young researchers a unique portfolio of multidisciplinary competences, cutting-edge proficiencies and transferable soft skills to push the boundaries of frontier research within the EU. The ESRs will be involved in all stages of drug development, ranging from Synthetic Chemistry over Medicinal Chemistry to Tumor Biology and Assay Development in a highly cross-linked, inter-sectoral research network between academia and industry. This network warrants cutting-edge interdisciplinary education, supplemented by a well-balanced and tailor-made training in transferable soft skills, directly focussed on the demands and needs of each individual researcher.

The ETN will recruit 15 highly talented early stage researchers (ESR) with background in the relevant scientific areas. This high complementarity is required for the different scientific tasks in the development pipeline. Vice versa, the ESRs will be exposed to a challenging research environment leading to a broad range of scientific competences to be acquired.

Eligibility criteria

All applicants must be Early-Stage Researchers (ESRs) who are in the first four years (full-time equivalent research experience) of their research careers, starting from the date when the M.Sc. degree (or similar) was awarded. They must not hold a doctoral degree.

Persons from any nationality may apply, but transnational mobility is indispensable: You may only apply for a position in a particular project if you did not reside or carry out your main activity (such as work or study) in this country for more than 12 months within the last 3 years. This excludes short stays such as holidays or compulsory national service.
Employment conditions
The selected candidates will receive a 36-month, full-time employment contract as per Marie Sklodowska-Curie Actions (MSCA) regulations for early stage researchers, starting at April 1st 2020. Marie Curie ITNs provide a highly competitive salary to the ESR, including a generous monthly living and mobility allowance and (if eligible) a monthly family allowance. The exact salary will be confirmed upon appointment. In particular, it consists of:
  • living allowance: 3.270 EUR/month (39.240 EUR/year), multiplied by the country correction coefficient of the country where the researcher is recruited:
    • Finland: 120.8%
    • Germany: 97.0%
    • Hungary: 77.4%
    • Italy: 104.4%
    • Switzerland: 121.2%
    • UK: 139.8%
  • mobility allowance: 600 EUR/month
  • family allowance, if applicable - depending on the family situation at the time when the contract is being concluded: 500 EUR/month
It must be noted that the living allowance is a gross EU contribution to the salary costs of the researcher. Consequently, the net salary results from deducting all compulsory social security contributions (employee and employer) as well as direct taxes (e.g. income tax) from the gross amounts. The rate indicated here is for researchers devoting themselves to their project on a full-time basis.

The mobility and family allowance is a fixed amount, regardless of the country of recruitment, and may be taxable depending on the country in which the researcher is recruited.

In the frame of a secondment, each ESR will spend seven months at the premises of another ETN consortium member. The transnational mobility rule does not apply for the secondments.

Further information regarding eligibility and salary can be found on the MSCA website.

Application Procedure

We are looking forward to hearing from you! Please download the application form via this link .

In order for your application to be considered please send the filled application form together with the following documents in English as single PDF-file to magicbullet@uni-bielefeld.de:
  • Completed application form
  • Curriculum vitae including relevant skills, experience and publication list
  • Motivation letter (1 page)
  • University transcripts and certificates: Bachelor and Master degrees. For EU Countries, the Diploma Supplement is recommended.
  • University entrance diploma

In addition, two reference letters from e.g. former supervisors are required that have to be sent separately and confidentially by the referees to magicbullet@uni-bielefeld.de.

Please notice that the individual requirements for each ESR project are mentioned in the list below.

Incomplete applications and all other ways or forms of application will not be considered! All applications will be deleted at the end of the selection procedure.

Application Deadline: 31.12.2019

ESR projects

ESR 01 - Bielefeld University, Germany

Implication of small molecule-drug conjugates containing HDAC inhibitors or tubulin-binding agents in immuno-oncology

Objectives

The ESR will be involved in the design and synthesis of conjugates comprising folic acid or peptides as homing devices and HDAC inhibitors or tubulin-binding agents as toxins, linked by hindered disulfides or protease-cleavable units. The evaluation of release mechanism and kinetics in plasma, tumor environment, and lysosome, as well as in vitro uptake studies will be performed.
Further information can be found here

We expect:

  • a relevant University degree (e. g. MSc in Organic Chemistry, Biochemistry, Life Science, Molecular Science, Medicinal Chemistry or related disciplines)
  • profound knowledge and practical experience in synthetic organic chemistry, documented in e.g. a MSc thesis or publication
  • practical experience in analytical methods (NMR, LC-MS, HPLC)
  • excellent English language skills
  • good abilities in scientific writing (reports, manuscripts)
  • team-oriented and cooperative working attitude
  • motivation and willingness to spend 7 months on secondment in another research group
  • motivation and willingness to present scientific results on conferences and to publish in scientific journals

Preferable additional qualifications:

  • Knowledge in bioconjugate chemistry / peptide chemistry / protein chemistry
  • experience with working in project teams

Please mention the job reference number wiss19246 in your application!
Supervisor
Prof. Dr. Norbert Sewald

Prof. Dr. Norbert Sewald

Bielefeld University, Germany

Organic & Bioorganic Chemistry

Planned Secondment Host for 7 months

Dr. Samuele Cazzamalli

Dr. Samuele Cazzamalli

Philochem AG, Switzerland

Discovery Center

Information about the processing of personal data provided by applicants for positions at Bielefeld University can be found here.
ESR 02 - Eötvös Loránd University, Hungary

Development of peptide drug conjugates for the treatment of cancers causing high mortality

Objectives

The ESR will be involved in the development of homing peptides to lung, pancreatic and brain cancers and in the investigation of different peptide-drug conjugates. The target receptors will be well known hormone peptide receptors (bombesin, somatostatin, neurotensin) as well as non-identified receptors that were selected by phage display technics. The ESR will identify unknown cell surface structures by affinity chromatography combined with HPLC-MS and protein data base search and study the stability and metabolism of the conjugates, as well as the in vitro anti-tumor activity of the conjugates alone and in combinations.

Further information can be found here

We expect:

  • a relevant University degree (e. g. MSc in Organic Chemistry, Biochemistry, Life Science, Molecular Science, Medicinal Chemistry or related disciplines)
  • profound knowledge and practical experience in synthetic organic chemistry, documented in e.g. a MSc thesis or publication
  • practical experience in analytical methods (NMR, LC-MS, HPLC)
  • excellent English language skills, certified by an official (EU) language exam
  • good abilities in scientific writing (reports, manuscripts)
  • team-oriented and cooperative working attitude
  • motivation and willingness to spend 7 months on secondment in another research group
  • motivation and willingness to present scientific results on conferences and to publish in scientific journals

Preferable additional qualifications:

  • Knowledge in bioconjugate chemistry / peptide chemistry / protein chemistry
  • experience with working in project teams
Supervisor
Prof. Dr. Gábor Mezõ

Prof. Dr. Gábor Mezõ

Eötvös Loránd University, Hungary

Research Group of Peptide Chemistry

Planned Secondment Host for 7 months

Dr. Daniela Modena

Dr. Daniela Modena

Italfarmaco, Italy

Cell Biology

ESR 03 - ETH Zürich, Switzerland

Design and synthesis of novel Small Molecule-Drug Conjugates for the treatment of tumors

Objectives

The focus of the Project will be on the discovery of ligands to tumor-associated antigens using DNA-encoded chemical libraries and on the engineering of those ligands into small molecule-drug conjugates, which will be tested for activity in vitro and in vivo.

Further information can be found here

Applicants should have a Master in Chemistry or chemical-related subject.

Applications should be directed to:

Prof. Dr. Dario Neri
Department of Chemistry and Applied Biosciences
Swiss Federal Institute of Technology (ETH Zürich)

Supervisor
Prof. Dr. Dario Neri

Prof. Dr. Dario Neri

ETH Zürich, Switzerland

Institute of Pharmaceutical Sciences

Planned Secondment Host for 7 months

Dr. Hans-Georg Lerchen

Dr. Hans-Georg Lerchen

Bayer Pharma AG, Germany

Medicinal Chemistry, DMPK

ESR 04 - Exiris SRL, Italy

Small molecule-drug conjugates containing HDAC inhibitors or tubulin-binding agents to enhance anti-tumor immune responses

Objectives

The ESR will be involved in the characterization of conjugates comprising folic acid or peptides as homing devices and HDAC inhibitors or tubulin-binding agents as toxins, linked by hindered disulfides or protease-cleavable units. The activity of the conjugates on murine tumor and immune cells in vitro and in syngeneic tumor models in vivo will be evaluated.
Further information can be found here

We expect:

  • a relevant University degree (e. g. MSc in Biology, Biochemistry, Pharmacy or related disciplines)
  • knowledge and practical experience in cell biology, molecular biology and/or molecular oncology/ immunology documented in e.g. a MSc thesis or publication
  • practical experience in cell culture, cell viability assays, microscopy, FACS and basic laboratory skills (molecular biology, electrophoresis, RNA extraction, Taqman PCR etc)
  • experience with in vivo work or willingness to learn in vivo techniques
  • excellent English language skills
  • good abilities in scientific writing (reports, manuscripts)
  • open, team-oriented and cooperative working attitude
  • motivation and willingness to spend 7 months on secondment in another research group
  • motivation and willingness to present scientific results on conferences and to publish in scientific journals

Preferable additional qualifications:

  • Basic knowledge in immunology, especially cancer immunology would be a plus
Supervisor
Dr. Christian Steinkühler

Dr. Christian Steinkühler

Exiris SRL, Italy

Oncology Research

Planned Secondment Host for 7 months

Prof. Dr. Pirjo Laakkonen

Prof. Dr. Pirjo Laakkonen

University of Helsinki, Finland

Research Programs Unit

ESR 05 - Fraunhofer ITEM, Germany

Identification of patient-specific targets to selectively treat tumor-associated macrophages (TAMs) in organotypic tumor slices of NSCLC and glioblastoma

Objectives

Glioblastoma multiforme (GBM) and Non-Small Cell Lung Cancer (NSCLC) have severe implications on quality of life and survival of diseased patients. TAMs were identified as prognostic marker in these cancer entities, repolarisation of TAM macrophages using RNA therapeutics was identified as a new potential therapy. Using viable human tumor tissue slices or tumor organoids, TAM related targets will be identified by phage display library and used for design of a drug delivery system to address repolarisation of TAMs. Efficacy of the treatments will be assessment in precision cut tumor tissues and spheroids.

Further information can be found here
Supervisor
Dr. Katherina Sewald

Dr. Katherina Sewald

Fraunhofer ITEM, Germany

Preclinical Pharmacology and in vitro Toxicology

Planned Secondment Host for 7 months

Dr. Giuseppe Roscilli

Dr. Giuseppe Roscilli

Takis Biotech SRL, Italy

Drug Evaluation and Monoclonal Antibodies

ESR 06 - Heidelberg Pharma Research GmbH, Germany

Amatoxin conjugates with small molecule targeting molecules for the treatment of cancer

Objectives

Selected small molecule target binders will be conjugated to a library of natural, semisynthetic and fully synthetic RNA-Pol-II inhibitors with optimized linker structures. Lead molecules for tumor targeting small molecules (e.g. DUPA for prostate-specific membrane antigen (PSMA)) or peptides. Optimal compounds will be selected by biological profiling in vitro and in vivo. Furthermore, optimization of bioidistribution will be performed by the regulation of pharmacokinetic half-life, e.g. fusion to Fc-fragments.

Further information can be found here

We expect:

  • MSc degree or Diploma from a recognized university in Chemistry / Biochemistry / Biology.
  • A strong background in organic chemistry and/or biochemistry including chromatographic techniques especially HPLC
  • A theoretical and practical knowledge in preclinical models of oncology including cell cultivation and cell viability assays.
  • Theoretical and practical knowledge in bioconjugate chemistry / peptide chemistry and drug labeling.
  • Practical experience in analytical methods (LC-MS, HPLC)
  • A background in cell culture and biochemical assays such as SDS-PAGE, Western Blotting, ELISA and cytometry.
  • excellent English language skills
  • Motivation and willingness to spend 7 months on secondment in another research group

Preferable additional qualifications:

  • Good abilities in scientific writing (reports, manuscripts)
  • Team-oriented and cooperative working attitude
  • Motivation and willingness to present scientific results on conferences and to publish in scientific journals
  • Experience with working in project teams
Supervisor
Prof. Dr. Andreas Pahl

Prof. Dr. Andreas Pahl

Heidelberg Pharma Research GmbH, Germany

Website

Planned Secondment Host for 7 months

Prof. Dr. Dario Neri

Prof. Dr. Dario Neri

ETH Zürich, Switzerland

Institute of Pharmaceutical Sciences

ESR 07 - National Institute of Oncology, Hungary

Investigation of the effect of newly synthesized compounds on tumor cell proliferation in vitro and on tumor growth and metastasis in vivo

Objectives

The ESR will be involved in the following research topics:
  • Investigation of selected molecules in different toxicology models
  • Investigation of the effect of selected molecules on tumor progression in vitro and in vivo
  • Target specification and validation
  • Establishment of in vivo orthotopic metastasis and patient-derived tumor xenografts (PDTX) models

Further information can be found here

We expect:

  • The applicants must have acquired a Master's degree or University diploma (completed five years of University education) from a recognized University in Biochemistry, Biotechnology, Pharmacology, Biology or Medicine.
  • The ideal candidates must have a strong background and practical experience in basic cell culture and molecular biological techniques.
  • Cell biology background with in vitro and in vivo drug development experiences
  • Interest in experimental animal models
  • Excellent English language skills (comprehension, speaking and writing)
  • Good abilities in scientific writing (reports, manuscripts)
  • Team-oriented and cooperative working attitude
  • Motivation and willingness to spend 7 months on secondment in another research group
  • Motivation and willingness to present scientific results on conferences and to publish in scientific journals

Preferable additional qualifications:

  • Prior experience in animal experiments
  • Background in Oncology, Pharmacology and testing cancer therapeutics
  • Experience with working in project teams
Supervisor
Dr. József Tóvári

Dr. József Tóvári

National Institute of Oncology, Hungary

Department of Experimental Pharmacology

Planned Secondment Host for 7 months

Prof. Dr. Andreas Pahl

Prof. Dr. Andreas Pahl

Heidelberg Pharma Research GmbH, Germany

Website

ESR 08 - Philochem AG, Switzerland

Design and synthesis of novel Small Molecule-Drug Conjugates for the treatment of tumors

Objectives

The ESR will be involved in the design and synthesis of anti-tumor Small Molecule-Drug Conjugate compounds and in vitro characterization, as well as the assessment of the efficacy of the novel SMDCs in animal models.
Further information can be found here

We expect:

  • a relevant University degree (e. g. MSc in Organic Chemistry, Biochemistry, Medicinal Chemistry or related disciplines)
  • profound knowledge and practical experience in synthetic organic chemistry, documented in e.g. a MSc thesis or publication
  • practical experience in analytical methods (NMR, LC-MS, HPLC)
  • excellent English language skills
  • good abilities in scientific writing (reports, manuscripts)
  • team-oriented and cooperative working attitude
  • motivation and willingness to perform in vivo experiments in relevant models (e.g. murine models of cancer)
  • motivation and willingness to spend 6 months on secondment in another research group
  • motivation and willingness to present scientific results on internal meetings, conferences and to publish in scientific journals

Preferable additional qualifications:

  • Knowledge in bioconjugate chemistry / peptide chemistry / protein chemistry
  • experience with working in project teams
  • experience with in vivo experiments in rodents
  • experience with in vitro bioactivity assays
Supervisor
Dr. Samuele Cazzamalli

Dr. Samuele Cazzamalli

Philochem AG, Switzerland

Discovery Center

Planned Secondment Host for 7 months

Prof. Dr. Norbert Sewald

Prof. Dr. Norbert Sewald

Bielefeld University, Germany

Organic & Bioorganic Chemistry

ESR 09 - Takis Biotech SRL, Italy

Development of scFv-drug conjugates containing HDAC inhibitors or tubulin-binding agents to enhance anti-tumor immune responses

Objectives

The ESR will be involved in the characterization of conjugates comprising scFv as homing devices and HDAC inhibitors or tubulin-binding agents as toxins, linked to lysines or to cysteins by protease-cleavable linkers. One of the target receptors could be ErbB3 tyrosine kinase receptor but also other receptors might be explored. The pharmacokinetic of the SCDCs and of the activity of the conjugates on murine or human tumors and immune cells in vitro will be evaluated. SCDCs will be evaluated in vivo in syngeneic mouse tumor models or in immunocompromised mice xenografted with human tumors and human immune system.
Further information can be found here

We expect:

  • a relevant University degree (e. g. MSc in Biology, Biomedical Science, Molecular Biology, Molecular Medicine, Biotechnology or related disciplines)
  • profound knowledge and practical experience in cellular, molecular biology and protein engineering applied in the oncology field, documented in e.g. a MSc thesis or publication
  • practical experience in cellular and molecular biology methods (cell culture, in vitro proliferation and apoptosis assay, FACS analysis, western-blot assay, ELISA assay) and recombinant protein and/or antibody expression and purification in mammalian systems and animal handling for biomedical research
  • excellent English language skills
  • good abilities in scientific writing (reports, manuscripts)
  • team-oriented and cooperative working attitude
  • motivation and willingness to spend 7 months on secondment in another research group
  • motivation and willingness to present scientific results on conferences and to publish in scientific journals

Preferable additional qualifications:

  • knowledge in protein engineering / bioinformatic tools / immunology
  • experience with working in project teams
Supervisor
Dr. Giuseppe Roscilli

Dr. Giuseppe Roscilli

Takis Biotech SRL, Italy

Drug Evaluation and Monoclonal Antibodies

Planned Secondment Host for 7 months

Prof. Dr. Pirjo Laakkonen

Prof. Dr. Pirjo Laakkonen

University of Helsinki, Finland

Research Programs Unit

ESR 10 - Technische Universität Darmstadt, Germany

Design and synthesis of Multivalent Peptide Drug Conjugates for tumor targeting

Objectives

The ESR will be involved in the synthesis and functional validation of peptide/toxin-drug conjugates that display potency in malignant tumors. Generation of multivalency via conjugation to dextran will be a preferred strategy to enhance selectivity and potency via direct cell killing or recruitment of immune effector cells. The efficacy of the newly generated compounds will be evaluated in cell culture models.

Further information can be found here

We expect:

  • a relevant University degree (e. g. MSc in Organic Chemistry, Biochemistry, Molecular Science, Medicinal Chemistry or related disciplines)
  • profound knowledge and practical experience in synthetic (bio)organic chemistry, preferably documented in e.g. a MSc thesis or publication
  • practical experience in analytical and preparative methods (NMR, LC-MS, HPLC)
  • very good English communication skills
  • team-oriented and cooperative working attitude
  • motivation and willingness to spend 7 months on secondment in another research group
  • high motivation to publish results in scientific journals with significant impact

Preferable additional qualifications:

  • Experimental experience in bioconjugate chemistry, peptide chemistry, or protein chemistry would be useful.
Supervisor
Prof. Dr. Harald Kolmar

Prof. Dr. Harald Kolmar

Technische Universität Darmstadt, Germany

Biochemistry

Planned Secondment Host for 7 months

Attila Kigyós

Attila Kigyós, MSc

Kineto Lab, Budapest

Website

ESR 11 - Universitá degli Studi dell´ Insubria, Italy

Integrin ligand-immunomodulating agent conjugates for targeted immunoncological therapy

Objectives

The ESR will be involved in the design and synthesis of antitumor conjugates consisting of peptidomimetic αvβ3 or α5β1 integrin ligands and small molecules modulating the tumor protein p53 activity, or peptides with chemokine like activity. Linking and release strategies will be optimized and biological studies in cancer cell lines will be performed.
Further information can be found here

We expect:

  • University degree which allows to pursue doctoral studies in Chemistry (e.g. MSc in Chemistry, Organic Chemistry or Medicinal Chemistry).
  • A strong knowledge and practical experience in synthetic organic chemistry, documented by MSc thesis or scientific publications.
  • Practical experience in analytical methods (NMR, MS, HPLC).
  • Excellent knowledge of the English language (comprehension, speaking and writing).
  • Good abilities in scientific writing (reports, manuscripts).
  • Team-oriented and cooperative working attitude.
  • Motivation and willingness to spend 7 months on secondment in another research group.
  • Motivation and willingness to present scientific results in conferences and to publish in scientific journals.

Preferable additional qualifications:

  • Background in medicinal chemistry and peptide chemistry.
  • Basic knowledge in biological assays.
  • Experience with working in a team.
Supervisor
Prof. Dr. Umberto Piarulli

Prof. Dr. Umberto Piarulli

Universitá degli Studi dell´ Insubria, Italy

Dipartimento di Scienza e Alta Tecnologia

Planned Secondment Host for 7 months

Prof. Dr. Andreas Pahl

Prof. Dr. Andreas Pahl

Heidelberg Pharma Research GmbH, Germany

Website

ESR 12 - Universitá degli Studi di Milano, Italy

Design and synthesis of trifunctional peptidomimetic scaffolds for DNA-Encoded Chemical Libraries (DECLs) in the oncology area.

Objectives

The ESR will be involved in the design and synthesis of peptidomimetic compounds as ligands for clinically-relevant tumor-associated antigens. The ligand design will be directed by screening of DNA-encoded chemical libraries (DECLs) as well as by literature data. In vitro binding affinity studies of the newly synthesized compounds for the cognate antigens will validate potential hits for further development.

Further information can be found here

We expect:

  • The applicants must have acquired a University diploma giving access to doctoral studies in Chemistry in the Country where the diploma was earned (typically a Master degree in Chemistry or Medicinal Chemistry).
  • The ideal candidates must have a strong background and practical experience in synthetic organic chemistry, documented by their MSc thesis.
  • Practical experience in analytical methods (NMR, MS, HPLC).
  • Excellent knowledge of the English language (comprehension, speaking and writing).
  • Good abilities in scientific writing (reports, manuscripts).
  • Team-oriented and cooperative working attitude.
  • Motivation and willingness to spend 7 months on secondment in another research group.
  • Motivation and willingness to present scientific results in conferences and to publish in scientific journals.

Preferable additional qualifications:

  • Background in medicinal chemistry and biochemical assays.
Supervisor
Prof. Dr. Cesare Gennari

Prof. Dr. Cesare Gennari

Universitá degli Studi di Milano, Italy

Dipartimento di Chimica

Planned Secondment Host for 7 months

Dr. Samuele Cazzamalli

Dr. Samuele Cazzamalli

Philochem AG, Switzerland

Discovery Center

ESR 13 - University of Cologne, Germany

Targeting mitochondria with PDCs for inducing apoptosis in cancer cells

Objectives

The PhD project will focus on the development of mitochondria-targeting peptide-drug conjugates (PDCs) that selectively activate apoptosis in cancer cells. The ESR will prepare peptides for organelle-specific drug delivery and synthesize PDCs. Different linkers for intracellular drug release, as well as different suitable cytotoxic payloads will be investigated. The novel PDCs will be screened in vitro concerning cellular uptake, mitochondria-targeting, changes in mitochondrial membrane potential and induction of apoptotic pathways.

Further information can be found here

We expect:

  • a relevant University degree (e. g. MSc in Biochemistry, Life Science, Molecular Science, Medicinal Chemistry or related disciplines)
  • profound knowledge and practical experience in methods from synthetic organic chemistry, or biochemistry documented in e.g. a MSc thesis or publication
  • excellent English language skills
  • good abilities in scientific writing (reports, manuscripts)
  • team-oriented and cooperative working attitude
  • motivation and willingness to spend 7 months on secondment in another research group
  • motivation and willingness to present scientific results on conferences and to publish in scientific journals

Preferable additional qualifications:

  • experience with cell culture
  • knowledge in bioconjugate chemistry / peptide chemistry / protein chemistry
  • practical experience in following methods (LC-MS, HPLC, flow cytometry)
  • experience with working in project teams

Supervisor
Prof. Dr. Ines Neundorf

Prof. Dr. Ines Neundorf

University of Cologne, Germany

Institute for Biochemistry

Planned Secondment Host for 7 months

Dr. Christian Steinkühler

Dr. Christian Steinkühler

Exiris SRL, Italy

Oncology Research

ESR 14 - University of Helsinki, Finland

Targeted drug delivery to primary and secondary brain tumours

Objectives

The ESR will be involved in the following research topics:
  • Combined analyses of RNA seq and drug sensitivity/resistance data of the glioblastoma and brain metastatic cells to identify novel drug molecules and affected signalling pathways
  • Delivery of drugs to glioblastomas and brain metastases (also other tumour types are possible) in vivo by using peptide/small molecule ligands for targeted treatment
  • Targeting the LMP-inducing drugs to tumours

Further information can be found here

We expect:

  • a relevant University degree (e. g. MSc Biochemistry, Life Science, Molecular Science, Biomedicine or related disciplines)
  • profound knowledge and practical experience in biochemistry and cell biology documented in e.g. a MSc thesis or publication(s)
  • license or willingness to obtain a licence to perform animal experimentation
  • excellent English language skills
  • good abilities in scientific writing (reports, manuscripts)
  • team-oriented and cooperative working attitude
  • motivation and willingness to spend 7 months on secondment in another research group
  • motivation and willingness to present scientific results on conferences and to publish in scientific journals

Preferable additional qualifications:

  • knowledge in bioinformatics
  • knowledge in tumour and/or vascular biology
  • knowledge in chemistry
Supervisor
Prof. Dr. Pirjo Laakkonen

Prof. Dr. Pirjo Laakkonen

University of Helsinki, Finland

Research Programs Unit

Planned Secondment Host for 7 months

Dr. Christian Steinkühler

Dr. Christian Steinkühler

Exiris SRL, Italy

Oncology Research

ESR 15 - University of Newcastle Upon Tyne, UK

Mass spectrometric analysis of peptide-drug conjugates in cells

Objectives

Peptide-drug conjugates are becoming exciting tools in delivering drugs into cells and tissues. Surprisingly little is known about the mode of action of delivery and drug release. In this project, the ESR will use state-of-the-art quantitative proteomics/mass spectrometry methods as well as biochemistry to study drug release from peptide-drug conjugates in cells.
Particularly, the ESR will be involved in the following research topics:
  • Identifying cellular distribution of compounds by subcellular fractionation followed by LC-MS
  • Identifying protein binding partners of compounds by cellular thermal shift assay mass spectrometry (CETSA MS)
  • Pharmacokinetics of compounds in cells (with Bayer)

Further information can be found here

We expect:

  • A relevant University degree (e. g. MSc in Mass Spectrometry, Biochemistry, Life Science, Molecular Science, Chemistry or related disciplines).
  • Profound knowledge and practical experience in biochemistry and/or cell biology and/or proteomics/mass spectrometry, documented in e.g. a MSc thesis or publication.
  • Ability to work independently and with high precision.
  • Excellent English language skills.
  • Good abilities in scientific writing (reports, manuscripts).
  • Team-oriented and cooperative working attitude.
  • Motivation and willingness to spend several months on secondment in another research group/pharmaceutical industry in a different country.
  • Motivation and willingness to present scientific results on conferences and to publish in scientific journals.

Preferable additional qualifications:

  • Knowledge in proteomics or mass spectrometry.
  • Knowledge in basic bioinformatics.
  • Knowledge in R.
  • Ability to work in a team of international researchers.
Supervisor
Prof. Dr. Matthias Trost

Prof. Dr. Matthias Trost

University of Newcastle Upon Tyne, UK

Institute for Cell and Molecular Biosciences

Planned Secondment Host for 10 months

Dr. Hans-Georg Lerchen

Dr. Hans-Georg Lerchen

Bayer Pharma AG, Germany

Medicinal Chemistry, DMPK